Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 14

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 14
---
 obtain listing on another reputable national securities exchange, a reduction in some or all of the following
may occur, each of which could materially adversely affect our stockholders.

On February 26, 2025, we received a letter
from Nasdaq notifying us that we were no longer in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq
under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Although Nasdaq has granted us 180 calendar days, or until August
25, 2025 (the “Compliance Period”) to regain compliance with the Bid Price Rule, in connection with the Panel’s approval
our appeal to regain compliance with the Stockholders’ Equity Rule (as defined under “The Private Placement”) as described
in more detail under “The Private Placement,” the Panel informed us that we are not eligible for an extension of the Compliance
Period and if we do not regain compliance with the Bid Price Rule during the Compliance Period, our Common Stock will be delisted. There
can be no assurance that we will regain such compliance during the Compliance Period.

Any delisting determination by Nasdaq could
seriously decrease or eliminate the value of an investment in our Common Stock and other securities linked to our Common Stock. While
a listing on an over-the-counter exchange could maintain some degree of a market in our Common Stock, we could face substantial material
adverse consequences, including, but not limited to, the following: limited availability for market quotations for our Common Stock;
reduced liquidity with respect to and decreased trading prices of our Common Stock; a determination that shares of our Common Stock are
“penny stock” under the Securities and Exchange Commission rules, subjecting brokers trading our Common Stock to more stringent
rules on disclosure and the class of investors to which the broker may sell the Common Stock; limited news and analyst coverage for our
Company, in part due to the “penny stock” rules; decreased ability to issue additional securities or obtain additional financing
in the future; and potential breaches under or terminations of our agreements with current or prospective large stockholders, strategic
investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect the market
price of our securities and trading volume of our Common Stock.

Furthermore, on May 7, 2025, the closing price
of our Common Stock was $0.1909. Pursuant to Nasdaq Rule 5810(c